Home / Intelligence / Case Studies / Biosimilar Differentiation Strategy
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries.
Geographic Scope: 
Client Situation:
The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars.
Trinity’s Solution
Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses, hospital administrators and payers.
Deliverables
- Catalogue of value-added services and contracts offered by the originator biologic across market segments
- Biosimilar defense strategies implemented by the manufacturer of the originator biologic
- Stakeholder influence map outlining formal and informal leverage points to drive biosimilar uptake
- Service offering and contracting expectations for biosimilars and impact on biosimilar differentiation
- Strategic recommendations to drive differentiation of a biosimilar
Project Outcomes & Impact
Trinity was able to support the client with driving differentiation of a biosimilar through service offerings and contracting, with strategies tailored to market segment.
Related Intelligence
Briefs
Unlocking Environmental Sustainability Opportunities in the Life Sciences
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments. Trinity Life Sciences has identified several recent trends driving this […]
Read More
Briefs
Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 […]
Read More
Briefs
Assessing the Influence of ICER Reports on U.S. Payer Decision Making
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute […]
Read More